PTC Therapeutics, Inc. PTCT closed lower on Thursday following the company’s decision to withdraw its New Drug Application for Translarna after receiving feedback from the U.S. Food and Drug ...

In a statement, PTC's chief executive, Matthew Klein, said the company had decided to pull the filing for Translarna (ataluren) as a treatment for nonsense mutation DMD after the FDA said it was ...

Boston, Massachusetts-based PTC Inc. (PTC) provides software solutions and services globally that aid manufacturing companies in designing, operating, and managing products. With a market cap. of $18.

Why PTC Stock Is Back in Focus After Earnings and New Client Win PTC (PTC) is back on many investors radar after a combination of better than expected quarterly results, higher full year guidance, and ...

Investing.com -- PTC Inc (NASDAQ:PTC) stock fell 3.8% on Thursday after Google announced a major upgrade to its Gemini 3 Deep Think AI system, potentially challenging PTC’s position in the engineering ...

Product design software company PTC (NASDAQ:PTC) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with ...

WARREN, N.J., Nov. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that it will host an R&D Day to discuss its pipeline on Dec. 2, 2025, at 9:30 a.m. EST in New York City. The ...

PTC Inc. (PTC) delivered earnings and revenue surprises of +20.47% and +7.43%, respectively, for the quarter ended December ...